Assays

384-well microplate
#Assays #Aurora Microplates #Drug development #Drug discovery #Lab technology #Podcast #Preclinical development

Podcast: How the tools you use impact precision in the lab

The latest sponsored DDW Sitting Down With podcast is now available. It features Charles Powell, CEO of Aurora Microplates, discussing how the Aurora microplate has evolved to keep up with changing trends within research and development. The microplate is a seemingly simple tool, yet it has… Read More

#News

384-well microplate
#Assays #Aurora Microplates #Drug development #Drug discovery #Lab technology #Preclinical development

How the tools you use impact consistency and precision in the lab

The latest sponsored DDW Sitting Down With podcast features Charles Powell, CEO of Aurora Microplates, discussing how the microplate has evolved to keep up with changing trends within research and development. The microplate is a seemingly simple tool, yet it has a crucial role to play… Read More

#Podcasts

Vaccine research
#Assays #Covid-19 #Drug efficacy #eBook #Immunology / Virology & Vaccines #Vaccines

eBook: Assessing the efficacy of vaccines through laboratory assays

The eighth eBook of the Hamilton series is now available to download for free. In ‘Assessing the Efficacy of Vaccines through Laboratory Assays‘, the authors discuss the key milestones achieved throughout the history of vaccine development, the laboratory tests commonly used to assess vaccines’ efficacy, and we… Read More

#News

#Assays #Covid-19 #Drug efficacy #Immunology / Virology & Vaccines #Vaccines

Assessing the efficacy of vaccines through laboratory assays

In the eighth eBook of the Hamilton series, ‘Assessing the Efficacy of Vaccines through Laboratory Assays’, we discuss: Vaccine development: Key milestones and impact of Covid-19 Laboratory tests commonly used to assess vaccines’ efficacy and the benefits of automating them Hamilton standardised and customised solutions for workflows such as qPCR,… Read More

#Resources

#Animal testing #ApconiX #Assays #FDA #Preclinical development

New podcast explores Sengenics’ i-Ome Discovery Microarrays

The latest sponsored DDW Sitting Down With podcast features Professor Jonathan Blackburn, Chief Scientific Officer of Sengenics, who discusses the advantages of functional protein microarrays, challenges to overcome for biomarker discovery, Sengenics’ new i-Ome Discovery… Read More

#News

Human brain
#Animal testing #ApconiX #Assays #FDA #Preclinical development #Sitting Down With podcast

Podcast: The FDA Modernisation Act 2.0 and seizure liability testing

The latest sponsored DDW Sitting Down With podcast is now available. It features Ruth Roberts and Michael Morton, co-founders of ApconiX, and Dr Kimberly Rockley, ApconiX, who discuss novel alternative methods and the impact of the FDA Modernisation Act 2.0 in relation to seizure liability as well as… Read More

#News

Human brain
#Animal testing #ApconiX #Assays #FDA #Preclinical development

How does the FDA Modernisation Act 2.0 impact seizure liability testing in drug discovery?

The latest sponsored DDW Sitting Down With podcast features Ruth Roberts and Michael Morton, co-founders of ApconiX, and Dr Kimberly Rockley, ApconiX, who discuss novel alternative methods and the impact of the FDA Modernisation Act 2.0 in relation to seizure liability as well as talking about the importance… Read More

#Podcasts

#App note #Assays #Drug development #Drug discovery #Kinetics #Sartorius

Download now: Optimise kinetic assays to avoid avidity effects

‘Optimising kinetic assays to avoid avidity effects’ – a new free resource – is now available from Sartorius and DDW. What you will learn: Researchers from ChromoTek discuss the differences between affinity and avidity as measured on the Octet BLI platform Measuring affinity in avidity driven assay orientations Why assay… Read More

#News

#Assays #Drug development #Drug discovery #Kinetics

Optimising kinetic assays to avoid avidity effects

What you will learn: Researchers from ChromoTek discuss the differences between affinity and avidity as measured on the Octet® BLI platform Measuring affinity in avidity driven assay orientations Why assay orientation, valency, ligand surface density and non-specific binding matter Recognise and resolve issues arising from interactions that contain a bivalent… Read More

#Resources

Two scientists in a research laboratory
#App note #Artificial intelligence (AI) #Assays #Cell culture #Cellular assays #Cellular imaging

Discover how to streamline migration assays with in-incubator monitoring

Cell migration assays can be time-consuming and challenging, from identifying and ensuring assays are imaged at the appropriate time, to properly measuring wound closure. In this new App Note, discover the benefits of Evident’s CM cell culture monitors, which provide label-free, quantitative results, consistent results throughout your lab, and are… Read More

#News

#Artificial intelligence (AI) #Assays #Cell culture #Cellular assays #Cellular imaging

Streamline migration assays with in-incubator monitoring

Cell migration assays can be time-consuming and challenging, from identifying and ensuring assays are imaged at the appropriate time, to properly measuring wound closure. Evident’s CM cell culture monitors provide label-free, quantitative results, consistent results throughout your lab, and are cost-effective. Researchers at ACEL simplified the cell migration process by… Read More

#Resources

#Animal models #Animal testing #Assays #Drug development #Drug discovery #Mouse models

Accelerating NDA filing through faster carcinogenicity assessment

Dr Megan MacBride and Dr Caroline Horizny Mitchell, Taconic, examine recent changes to animal testing in drug design. Drug discovery and development is an arduous process that can cost upwards of $2.6 billion and take over 10 years. While the discovery phase – which includes target discovery, target validation, lead… Read More

#Exclusive Content

#Assays #Biotechnology #DNA #Next generation sequencing #Research

Key acquisition for next generation sequencing research assays

Integrated DNA Technologies has purchased next generation sequencing (NGS) research assays from Invitae Corporation under the trademarked name Archer.   The integration of IDT’s portfolio with the acquired NGS research assays—which have been foundational in researching novel cancer fusions—will empower labs with a solution to uncover biomarkers and… Read More

#News

#Assays #Drug discovery #Lab analytics

Make the switch to label-free interaction analysis

Conventional bioassays rely on enzyme or fluorescent labels to detect biomolecular interactions. These come with challenges that lead to skewed and inaccurate results. In this eBook, learn how label-free interaction techniques drive: Faster analysis – fewer sample preparation steps More sensitive analysis – enabling close observation of small and fragment molecules… Read More

#Intelligence #Resources

#Assays #Drug discovery #Multiplexing #Screening

What you need to know about multiplexing in drug discovery

Download this guide from Abcam to learn more about: How multiplexing generates more insightful data The key principles, benefits and limitations of different multiplex assays How to select the most suitable multiplex assay for your screening program Click here to download… Read More

#News